Ion-Pair Reversed-Phase (IP-RP) LCMS-9030 (Q-TOF) Mass Spectrometer for Separation and Identification of Oligonucleotides

User Benefits

- High-resolution separation of 10 to 60 base oligonucleotides using an ion-pairing buffer system - High-accuracy mass analysis of oligonucleotides using LCMS-9030 (Q-TOF) mass spectrometer

Introduction

Oligonucleotide therapeutics are short synthetic DNA or RNA polymers with the potential to treat a wide range of diseases. Currently, 13 oligonucleotide therapeutics have been granted new drug approval (NDA) by the U.S. Food and Drug Administration (FDA). On December 11, 2020, the US. FDA issued the first emergency use authorization (EUA) for the PfizerBioNTech COVID-19 mRNA Vaccine to be used in the US, which has further spurred interest in the oligonucleotide therapeutics. Typical oligonucleotides therapeutics are approximately 15-30 bases, except aptamer oligonucleotides, which are commonly 40-60 bases. While shorter oligonucleotides (less than 20 bases) can be easily resolved by HPLC, the separation of longer sequences becomes progressively more challenging. This article introduces an ion-pair reversed-phase (IP-RP) LC-MS system for high-resolution separation and highaccuracy mass analysis of oligonucleotides. Shimadzu LCMS-9030 (Q-TOF) mass spectrometer is used for LCMS analysis.

November 29, 2021 GMT